Novartis AG ADR (NVS)vsRapport Therapeutics, Inc. Common Stock (RAPP)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
RAPP
Rapport Therapeutics, Inc. Common Stock
$43.62
+0.37%
HEALTHCARE · Cap: $2.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 283365% more annual revenue ($56.69B vs $20.00M). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
RAPP
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for RAPP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : RAPP
The strongest argument for RAPP centers on Debt/Equity, Altman Z-Score.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : RAPP
The primary concerns for RAPP are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RAPP carries more volatility with a beta of 1.03 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 24/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Rapport Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases, especially Alzheimer's and associated cognitive disorders. Utilizing proprietary drug candidates and cutting-edge technology platforms, the firm is focused on meeting significant unmet medical needs through comprehensive scientific research and clinical trials. With a robust pipeline of innovative treatment options, Rapport Therapeutics is strategically poised to reshape the treatment paradigm for individuals facing the challenges of cognitive impairments, enhancing patient quality of life and contributing to the broader healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?